BioDelivery Sciences International, Inc. - BDSI STOCK NEWS

BioDelivery Sciences International (NASDAQ: BDSI) announced participation in the virtual Southwest IDEAS Investor Conference on November 18, 2020. CEO Jeffrey Bailey and CFO Terry Coelho will present, with the webcast available at 7:00 am CST. Interested investors can access the presentation through the conference portal and BDSI's investor relations section. IDEAS Conferences focus on connecting quality companies with investment professionals, providing an independent venue for showcasing investment opportunities.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reported a 30% increase in net revenue for Q3 2020, achieving a record $39.4 million. This growth was fueled by BELBUCA net sales of $34.8 million and Symproic sales of $3.5 million. The company reached all-time high prescriptions for both products. GAAP net income stood at $9.4 million, with a 34% EBITDA margin. The Board authorized a $25 million share repurchase program. Cash and cash equivalents reached $100.2 million as of September 30, 2020. A conference call is scheduled for November 5, 2020.

BioDelivery Sciences International (NASDAQ: BDSI) announced a $25 million share repurchase program authorized by its Board of Directors, reflecting confidence in the Company’s long-term outlook and ability to generate strong cash flow. CEO Jeff Bailey emphasized a balanced approach to capital allocation, focusing on both repurchases and investments in organic growth and strategic acquisitions to enhance shareholder value. Repurchases will be executed at management's discretion based on market conditions, utilizing existing cash.

BioDelivery Sciences International (NASDAQ: BDSI) announced Jeff Bailey has been appointed as the permanent Chief Executive Officer (CEO) effective November 4, 2020. Bailey previously served as interim CEO since May 2020 and has extensive experience in the pharmaceutical sector. His leadership is expected to enhance the company’s growth strategy, leveraging BDSI's innovative products and solid balance sheet. The Board expressed confidence in his vision to drive long-term shareholder value amidst ongoing challenges in the industry.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will report its Q3 2020 financial results on November 5, 2020, before U.S. market open. A conference call and webcast will take place at 8:30 AM ET on the same day to discuss the results and update on business operations. BDSI focuses on chronic conditions and leverages its proprietary BEMA® technology to address serious medical needs, including chronic pain and opioid-induced constipation.

BioDelivery Sciences International (NASDAQ: BDSI) presented five scientific posters on BELBUCA at the 14th Annual PAINWeek 2020 Conference held virtually on September 11-13, 2020. The studies highlighted the efficacy of BELBUCA in managing chronic pain compared to oral oxycodone, including key outcomes and pharmacodynamics. Chief Medical Officer Thomas Smith stated that this presentation enhances awareness of BELBUCA as a significant treatment option for chronic pain patients. Full details about the posters can be accessed on the PAINWeek Conference website.

BioDelivery Sciences International (BDSI) reported a 23% increase in net revenue for Q2 2020, reaching $36.6 million, driven by a 34% rise in BELBUCA sales to $32.3 million. Symproic sales grew by 7% to $3.4 million. BELBUCA prescriptions hit a record 104,687, reflecting a 31% increase. Despite a net income of $1.2 million, down from $5.0 million in Q1 2020, BDSI maintains a solid cash position of $91 million. The company has adapted its commercial model amid COVID-19 challenges. A conference call is scheduled for today at 8:30 AM ET.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will report its Q2 2020 financial results on August 5, 2020, before U.S. markets open. A conference call is scheduled for 8:30 AM ET to discuss these results and provide updates on operations. The company focuses on chronic conditions and leverages its proprietary BEMA® technology for product development. BDSI offers solutions for conditions like chronic pain and opioid-induced constipation, ensuring comprehensive care for patients.

BioDelivery Sciences International (NASDAQ: BDSI) announced that Jeffrey Bailey, Interim CEO, and CFO Terry Coelho will present at two investor conferences in June 2020. The Jefferies Virtual Healthcare Conference is scheduled for June 2 at 3:00 PM ET, followed by the William Blair 40th Annual Growth Stock Conference on June 11 at 9:40 AM ET. Attendees can access the webcasts for both events via provided links. A replay will be available on the company's website for 60 days. BDSI focuses on therapies for chronic conditions, including pain management and opioid dependence.